(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Delight of Perusing: Book Proposals for Each Class - 2Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
- 3'Backward and upward and tilted': Spaceflight causes astronauts' brains to shift inside their skulls
- 4Which Diet Prompts the Incomparable Wellbeing Results?
- 5Putin critic gets six years in penal colony, vows hunger strike
- Vote In favor of Your Favored Kind Of Attire
- Flat Earth, spirits and conspiracy theories – experience can shape even extraordinary beliefs
- Medical team successfully delivers baby and removes massive tumor
- Chinese mega embassy could bring security advantages, says No 10
- 10 Demonstrated Systems to Develop Your Internet based Business
- Undeniably popular Historical centers: Where Craftsmanship and History Meet
- Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- Practice environmental safety in Style: Divulging Famous Electric Vehicle Brands
- Syria rejects forced deportations from Germany amid migration debate
